Evidence map›Paper›PMID 34357552›Full record

ArticleMetabolic brain disease2021

Neuroprotective effects of coenzyme Q10 in Parkinson's model via a novel Q10/miR-149-5p/MMPs pathway.

Elham Ghasemloo, Hossein Mostafavi, Masoumeh Hosseini, Meysam Forouzandeh, Mehdi Eskandari, Seyyed Saeid Mousavi

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Neuroprotection in Parkinson Disease.Neurology and therapy · 2025
    Review
  3. Review
  4. Early diagnosis of Parkinson's disease: biomarker study.Frontiers in aging neuroscience · 2025
    Review
  5. Review
  6. Article
  7. Quinones as Neuroprotective Agents.Antioxidants (Basel, Switzerland) · 2023
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Elham GhasemlooDepartment of Physiology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Hossein MostafaviDepartment of Physiology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran. mostafavih@zums.ac.com.
Masoumeh HosseiniLaboratory Expert Department of Physiology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Meysam ForouzandehFaculty of Life Sciences, Shahid-Beheshti University, Tehran, Iran.
Mehdi EskandariDepartment of Physiology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Seyyed Saeid MousaviAnimal Science Research Department, Zanjan Agricultural and Natural Resources Research and Education Center, AREEO, Zanjan, Iran.
Zanjan University of Medical Sciences · IRAgricultural Research & Education Organization · IRShahid Beheshti University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a complex neurodegenerative disease in which the understanding of the underlying molecular mechanisms can be constructive in the diagnosis and treatment. Matrix metalloproteinase (MMPs) elevation and damage to the blood-brain barrier (BBB) are critical mechanisms involved in the PD separation. Studies have revealed that changes in miR-149-5p and CoQ10 are associated with BBB damage, and CoQ10 can affect the levels of some miRs. Hence, in the present study, we aimed to evaluate CoQ10 and miR-149-5p mimic on miR-149-5p, MMPs and TH expression, and behavioral functions of the PD models. PD was induced by injection of 6-OHDA into the rats' Medial Forbrain Bundle (MFB). The behavioral tests, including the Rotation test, Rotarod test, and Open field test, have been directed two weeks after PD induction. Next, the MiR-149-5p mimic (miR-mimic) and CoQ10 have been administered to rats. The same behavioral tests have been evaluated two weeks after administration to investigate the effect of miR-149-5p mimic and CoQ10. The rats were followed extra four weeks, and the behavioral tests have performed again. Finally, the expression of MMPs and miR-149-5p genes was measured using RT-qPCR, and tyrosine hydroxylase (TH) was assessed through immunohistochemistry analysis. According to the obtained results, the level of miR-149-5p has decreased, followed by PD induction in rats. RT-qPCR analysis has represented upregulation and downregulation of miR-149-5p and MMP-2,9, respectively, after miR-mimic and CoQ10 treatment. The treated rats have also represented improved motor function and increased TH +  cells in the striatum according to the behavioral tests and immunohistochemistry assay. Taking together miR-149 and CoQ10 has shown to have an impressive potential to prevent damage to dopaminergic neurons caused by 6-OHDA injection through reducing MMP-2,9, increased TH expression, and improved motor function.

Indexed as

MicroRNAsNeurodegenerative DiseasesNeuroprotective AgentsParkinson DiseaseAnimalsDisease Models, AnimalMatrix MetalloproteinasesOxidopamineRatsUbiquinonecoenzyme Q10Matrix MetalloproteinasesMicroRNAsNeuroprotective AgentsOxidopamineUbiquinoneCoenzym Q10Matrix metalloproteinasemiR-149-5p mimicParkinson's diseaseTyrosine hydroxylase

Identifiers

PMID34357552
OpenAlexW3190695775

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.